文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

D指数指导的早期抗真菌治疗与经验性抗真菌治疗持续性发热性中性粒细胞减少症的随机对照非劣效性试验

D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
PubMed 文献 · J Clin Oncol · 2020-01-24

该多中心开放标签随机对照非劣效性试验纳入423例血液恶性肿瘤化疗或造血干细胞移植后持续性发热性中性粒细胞减少症患者,比较D指数指导的早期抗真菌治疗(DET)与经验性抗真菌治疗(EAT)。意向性分析413例中, probable/proven侵袭性真菌感染发生率EAT组2.5%、DET组0.5%,满足非劣效性标准(-2.0%;90% CI,-4.0%至0.1%);DET组米卡芬净使用率显著降低(60.2% vs 32.5%;P < .001),生存率无差异。

要点

  • DET策略在持续性FN患者中不劣于EAT,侵袭性真菌感染率低。
  • DET显著减少米卡芬净使用(32.5% vs 60.2%;P < .001)。
  • DET可作为经验性或抢先抗真菌治疗的合理替代方案。

核心结论

  • DET策略在不增加侵袭性真菌感染的前提下减少抗真菌药物使用和费用,可作为经验性或抢先抗真菌治疗的合理替代。

研究设计与样本

  • 多中心开放标签非劣效性随机对照试验,纳入423例血液恶性肿瘤化疗或造血干细胞移植后持续性发热性中性粒细胞减少症患者,随机分为EAT组或DET组。
  • DET组推迟抗真菌治疗直至D指数达到5,500或血清/影像学检查阳性。
  • 允许预防性使用除多烯类、棘白菌素类或伏立康唑以外的抗真菌药物。
  • EAT或DET均使用米卡芬净150 mg/日。

主要发现

  • 意向性分析413例中,probable/proven侵袭性真菌感染发生率EAT组2.5%、DET组0.5%。
  • 非劣效性标准达到(-2.0%;90% CI,-4.0%至0.1%)。
  • 第42天生存率EAT组98.0%、DET组98.6%;第84天生存率EAT组96.4%、DET组96.2%。
  • 米卡芬净使用率DET组显著低于EAT组(32.5% vs 60.2%;P < .001)。

关键数值与推荐

  • D指数计算为中性粒细胞曲线与中性粒细胞计数500/μL水平线围成的面积,反映中性粒细胞减少的持续时间和深度。
  • DET组抗真菌治疗推迟至D指数达到5,500或血清/影像学检查阳性。
  • 非劣效性标准:DET组与EAT组侵袭性真菌感染率差异的90% CI上限低于预设界值(-2.0%;90% CI,-4.0%至0.1%)。

临床怎么用

  • 对持续性发热性中性粒细胞减少症患者,可采用D指数指导的早期抗真菌治疗策略,推迟抗真菌治疗至D指数≥5,500或血清/影像学阳性。
  • 该策略可显著减少米卡芬净使用,且不增加侵袭性真菌感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Empiric antifungal therapy (EAT) is recommended for persistent febrile neutropenia (FN), but in most patients, it is associated with overtreatment. The D-index, calculated as the area surrounded by the neutrophil curve and the horizontal line at a neutrophil count of 500/μL, reflects both the duration and depth of neutropenia and enables real-time monitoring of the risk of invasive fungal infection in individual patients at no cost. We investigated a novel approach for patients with persistent FN called D-index-guided early antifungal therapy (DET), in which antifungal treatment is postponed until a D-index reaches 5,500 or the detection of positive serum or imaging tests, and compared it with EAT in this multicenter open-label noninferiority randomized controlled trial. PATIENTS AND METHODS: We randomly assigned 423 patients who underwent chemotherapy or hematopoietic stem-cell transplantation for hematologic malignancies to the EAT or DET group. The prophylactic use of antifungal agents other than polyenes, echinocandins, or voriconazole was allowed. Micafungin at 150 mg per day was administered as EAT or DET. RESULTS: In an intent-to-treat analysis of 413 patients, the incidence of probable/proven invasive fungal infection was 2.5% in the EAT group and 0.5% in the DET group, which fulfilled the predetermined criterion of noninferiority of the DET group (-2.0%; 90% CI, -4.0% to 0.1%). The survival rate was 98.0% versus 98.6% at day 42 and 96.4% versus 96.2% at day 84. The use of micafungin was significantly reduced in the DET group (60.2% v 32.5%; P < .001). CONCLUSION: A novel strategy, DET, decreased the use and cost of antifungal agents without increasing invasive fungal infections and can be a reasonable alternative to empiric or preemptive antifungal therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kanda Y, Kimura SI, Iino M, et al. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020. PMID: 31977270. doi:10.1200/JCO.19.01916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。